相似文献
1
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Int J Mol Sci. 2022 Jan 20;23(3):1096. doi: 10.3390/ijms23031096.
2
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.
3
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Am Soc Clin Oncol Educ Book. 2015:e648-55. doi: 10.14694/EdBook_AM.2015.35.e648.
4
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300.
5
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Oncogene. 2019 Oct;38(42):6835-6849. doi: 10.1038/s41388-019-0929-9. Epub 2019 Aug 12.
6
[I. Identification of a Possible Therapeutic Target for Chondrosarcoma with IDH Mutant Inhibitors].
Gan To Kagaku Ryoho. 2017 Mar;44(3):212-216.
7
Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Arch Pathol Lab Med. 2021 Aug 1;145(8):1009-1017. doi: 10.5858/arpa.2020-0379-OA.
8
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Hum Pathol. 2017 Jul;65:239-246. doi: 10.1016/j.humpath.2017.05.015. Epub 2017 May 25.
9
Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
Crit Rev Oncol Hematol. 2018 Nov;131:102-109. doi: 10.1016/j.critrevonc.2018.09.001. Epub 2018 Sep 12.
10
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.
Nat Genet. 2013 Aug;45(8):923-6. doi: 10.1038/ng.2668. Epub 2013 Jun 16.
引用本文的文献
1
Clinicopathologic and proteomic characteristics of low-grade undifferentiated spindle cell sarcoma.
Front Mol Biosci. 2025 Jul 1;12:1591644. doi: 10.3389/fmolb.2025.1591644. eCollection 2025.
2
Exploring the causal relationship between immune factors and chondrosarcoma: a Mendelian randomization study.
Discov Oncol. 2025 May 18;16(1):801. doi: 10.1007/s12672-025-02654-5.
3
Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis.
BMC Cancer. 2025 May 9;25(1):852. doi: 10.1186/s12885-025-14281-y.
4
Maxillary aggressive chondrosarcoma: A rare and challenging case.
Radiol Case Rep. 2025 Mar 8;20(5):2521-2526. doi: 10.1016/j.radcr.2025.02.003. eCollection 2025 May.
5
Impact of the Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor in Conventional Chondrosarcoma.
Indian J Surg Oncol. 2025 Feb;16(1):356-363. doi: 10.1007/s13193-024-02100-y. Epub 2024 Sep 23.
6
DNA methyltransferase 3A: A prognostic biomarker and potential target for immunotherapy in gastric cancer.
Medicine (Baltimore). 2025 Feb 14;104(7):e41578. doi: 10.1097/MD.0000000000041578.
7
Research trends and foci in chondrosarcoma: A bibliometric and network analysis.
Medicine (Baltimore). 2024 Nov 8;103(45):e40403. doi: 10.1097/MD.0000000000040403.
8
RNF2 promotes chondrosarcoma progression by regulating ubiquitination and degradation of CBX7.
Cancer Metab. 2024 Oct 25;12(1):30. doi: 10.1186/s40170-024-00359-x.
9
Multiple enchondromas in Ollier's disease: A case report.
Radiol Case Rep. 2024 Aug 19;19(11):5033-5037. doi: 10.1016/j.radcr.2024.07.080. eCollection 2024 Nov.
10
Keratin 17 and Collagen type 1 genes: Esophageal cancer molecular marker discovery and evaluation.
Clin Respir J. 2024 Jul;18(7):e13793. doi: 10.1111/crj.13793.
本文引用的文献
1
Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.
Mol Oncol. 2022 Jun;16(11):2174-2194. doi: 10.1002/1878-0261.13160. Epub 2022 Jan 1.
2
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Cells. 2021 Oct 26;10(11):2893. doi: 10.3390/cells10112893.
3
The Key Gene Expression Patterns and Prognostic Factors in Malignant Transformation from Enchondroma to Chondrosarcoma.
Front Oncol. 2021 Sep 10;11:693034. doi: 10.3389/fonc.2021.693034. eCollection 2021.
4
Targeting of cancer cell death mechanisms by resveratrol: a review.
Apoptosis. 2021 Dec;26(11-12):561-573. doi: 10.1007/s10495-021-01689-7. Epub 2021 Sep 25.
5
Prognostic impact of IDH mutations in chondrosarcoma.
J Orthop Sci. 2022 Nov;27(6):1315-1322. doi: 10.1016/j.jos.2021.07.024. Epub 2021 Sep 14.
6
SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone.
Cancers (Basel). 2021 Jul 29;13(15):3823. doi: 10.3390/cancers13153823.
7
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
Cancer Med. 2021 Jul;10(13):4415-4423. doi: 10.1002/cam4.4019. Epub 2021 Jun 3.
8
Chondrosarcoma-from Molecular Pathology to Novel Therapies.
Cancers (Basel). 2021 May 14;13(10):2390. doi: 10.3390/cancers13102390.
9
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence.
Cancers (Basel). 2021 May 17;13(10):2408. doi: 10.3390/cancers13102408.
10
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
Eur J Cancer. 2021 Jun;150:108-118. doi: 10.1016/j.ejca.2021.03.039. Epub 2021 Apr 22.
Zotero 插件